Skip to main content Accessibility help

Pompe Disease: Diagnosis and Management. Evidence-Based Guidelines from a Canadian Expert Panel

  • Mark Tarnopolsky (a1) (a2) (a3), Hans Katzberg (a4) (a5), Basil J. Petrof (a6), Sandra Sirrs (a7), Harvey B. Sarnat (a8), Kimberley Myers (a9), Nicolas Dupré (a10) (a11), Dubravka Dodig (a12), Angela Genge (a13), Shannon L. Venance (a14), Lawrence Korngut (a15), Julian Raiman (a16) (a17) and Aneal Khan (a18) (a19)...


Pompe disease is a lysosomal storage disorder caused by a deficiency of the enzyme acid alpha-glucosidase. Patients have skeletal muscle and respiratory weakness with or without cardiomyopathy. The objective of our review was to systematically evaluate the quality of evidence from the literature to formulate evidence-based guidelines for the diagnosis and management of patients with Pompe disease. The literature review was conducted using published literature, clinical trials, cohort studies and systematic reviews. Cardinal treatment decisions produced seven management guidelines and were assigned a GRADE classification based on the quality of evidence in the published literature. In addition, six recommendations were made based on best clinical practices but with insufficient data to form a guideline. Studying outcomes in rare diseases is challenging due to the small number of patients, but this is in particular the reason why we believe that informed treatment decisions need to consider the quality of the evidence.

Diagnostic et prise en charge de la maladie de Pompe : lignes directrices fondées sur des données probantes, élaborées par un comité d’experts. La maladie de Pompe est une maladie de surcharge lysosomale due à un déficit en alpha-glucosidase acide. Les patients présentent une faiblesse des muscles squelettiques ainsi qu’une atteinte respiratoire, avec ou sans cardiomyopathie. Le but de notre revue était d’évaluer systématiquement la qualité des données de la littérature sur ce sujet et d’élaborer des lignes directrices fondées sur des données probantes pour le diagnostic et la prise en charge des patients atteints de la maladie de Pompe. Nous avons procédé à une revue de la littérature incluant les essais cliniques, les études de cohorte et les revues systématiques. Sept lignes directrices de traitement ont été élaborées concernant les décisions fondamentales de traitement et nous les avons classées au moyen de la méthodologie GRADE (Grading of Recommendations Assessment, Development and Evaluation) évaluant la qualité des données de la littérature. De plus, nous avons émis 6 recommandations fondées sur des pratiques cliniques exemplaires, mais pour lesquelles les données étaient insuffisantes pour établir une ligne directrice. L’étude des résultats du traitement de maladies rares constitue un défi à cause du petit nombre de patients atteints de ces maladies. Cependant c’est la raison pour laquelle nous croyons qu’il est important de considérer la qualité des données disponibles afin de prendre des décisions de traitement éclairées.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Pompe Disease: Diagnosis and Management. Evidence-Based Guidelines from a Canadian Expert Panel
      Available formats

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Pompe Disease: Diagnosis and Management. Evidence-Based Guidelines from a Canadian Expert Panel
      Available formats

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Pompe Disease: Diagnosis and Management. Evidence-Based Guidelines from a Canadian Expert Panel
      Available formats


Corresponding author

Correspondence to: Aneal Khan, Associate Professor of Medical Genetics and Paediatrics, University of Calgary, Alberta Children’s Hospital, 2888 Shaganappi Trail NW, Calgary, Alberta, Canada T3B 6A8. Email:


Hide All
1. Kishnani, PS, Steiner, RD, Bali, D, Berger, K, Byrne, BJ, Case, LE, et al. Pompe disease diagnosis and management guideline. Genet Med. 2006;8(5):267-288.
2. Centre for Evidence-Based Medicine, OCEBM Levels of Evidence Working Group. The Oxford Levels of Evidence, 2.1. Available from
3. Guyatt, G, Gutterman, D, Baumann, MH, Addrizzo-Harris, D, Hylek, EM, Phillips, B, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest. 2006;129(1):174-181.
4. Kishnani, PS, Howell, RR. Pompe disease in infants and children. J Pediatr. 2004;144(Suppl 5):S35-S43.
5. Kishnani, PS, Hwu, WL, Mandel, H, Nicolino, M, Yong, F, Corzo, D. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006;148(5):671-676.
6. Byrne, BJ, Kishnani, PS, Case, LE, Merlini, L, Müller-Felber, W, Prasad, S, et al. Pompe disease: design, methodology, and early findings from the Pompe Registry. Mol Genet Metab. 2011;103(1):1-11; Erratum in: Mol Genet Metab. 2011;104(3):424.
7. van den Hout, HM, Hop, W, van Diggelen, OP, Smeitink, JA, Smit, GP, Poll-The, BT, et al. The natural course of infantile Pompe’s disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003;112(2):332-340.
8. Jones, HN, Muller, CW, Lin, M, Banugaria, SG, Case, LE, Li, JS, et al. Oropharyngeal dysphagia in infants and children with infantile Pompe disease. Dysphagia. 2010;25(4):277-283.
9. Hamdan, MA, El-Zoabi, BA, Begam, MA, Mirghani, HM, Almalik, MH. Antenatal diagnosis of Pompe disease by fetal echocardiography: impact on outcome after early initiation of enzyme replacement therapy. J Inherit Metab Dis. 2010;33(Suppl 3):S333-S339.
10. Barker, PC, Pasquali, SK, Darty, S, Ing, RJ, Li, JS, Kim, RJ, et al. Use of cardiac magnetic resonance imaging to evaluate cardiac structure, function and fibrosis in children with infantile Pompe disease on enzyme replacement therapy. Mol Genet Metab. 2010;101(4):332-337.
11. Chen, LR, Chen, CA, Chiu, SN, Chien, YH, Lee, NC, Lin, MT, et al. Reversal of cardiac dysfunction after enzyme replacement in patients with infantile-onset Pompe disease. J Pediatr. 2009;155(2):271-275.
12. Prater, SN, Banugaria, SG, DeArmey, SM, Botha, EG, Stege, EM, Case, LE, et al. The emerging phenotype of long-term survivors with infantile Pompe disease. Genet Med. 2012;14(9):800-810.
13. Sacconi, S, Wahbi, K, Theodore, G, Garcia, J, Salviati, L, Bouhour, F, et al. Atrio-ventricular block requiring pacemaker in patients with late-onset Pompe disease. Neuromuscul Disord. 2014;24(7):648-650.
14. Fung, KP, Lo, RN, Ho, HC. Pompe’s disease presenting as supraventricular tachycardia. Aust Paediatr J. 1989;25(2):101-102.
15. Hagemans, ML, Winkel, LP, Hop, WC, Reuser, AJ, van Doorn, PA, van der Ploeg, AT. Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology. 2005;64(12):2139-2141.
16. Hagemans, ML, Winkel, LP, van Doorn, PA, Hop, WJ, Loonen, MC, Reuser, AJ, et al. Clinical manifestation and natural course of late-onset Pompe’s disease in 54 Dutch patients. Brain. 2005;128(Pt 3):671-677.
17. Ausems, MG, Verbiest, J, Hermans, MP, Kroos, MA, Beemer, FA, Wokke, JH, et al. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet. 1999;7(6):713-716.
18. van der Beek, NA, Hagemans, ML, Reuser, AJ, Hop, WC, van der Ploeg, AT, van Doorn, PA, et al. Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. Neuromuscul Disord. 2009;19(2):113-117.
19. Güngör, D, de Vries, JM, Hop, WC, Reuser, AJ, van Doorn, PA, van der Ploeg, AT, et al. Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy. Orphanet J Rare Dis. 2011;6:34.
20. Schuller, A, Wenninger, S, Strigl-Pill, N, Schoser, B. Toward deconstructing the phenotype of late-onset Pompe disease. Am J Med Genet C Semin Med Genet. 2012;160C(1):80-88.
21. Laforêt, P, Nicolino, M, Eymard, PB, Puech, JP, Caillaud, C, Poenaru, L, et al. Juvenile and adult-onset acid maltase deficiency in France: genotype–phenotype correlation. Neurology. 2000;55(8):1122-1128.
22. van der Beek, NA, de Vries, JM, Hagemans, ML, Hop, WC, Kroos, MA, Wokke, JH, et al. Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study. Orphanet J Rare Dis. 2012;7:88.
23. Hagemans, ML, Hop, WJ, van Doorn, PA, Reuser, AJ, van der Ploeg, AT. Course of disability and respiratory function in untreated late-onset Pompe disease. Neurology. 2006;66(4):581-583.
24. Wokke, JH, Escolar, DM, Pestronk, A, Jaffe, KM, Carter, GT, van den Berg, LH, et al. Clinical features of late-onset Pompe disease: a prospective cohort study. Muscle Nerve. 2008;38(4):1236-1245.
25. Müller-Felber, W, Horvath, R, Gempel, K, Podskarbi, T, Shin, Y, Pongratz, D, Walter, MC, et al. Late-onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord. 2007;17(9-10):698-706.
26. Laforêt, P, Nicolino, M, Eymard, B, Puech, JP, Caillaud, C, Poenaru, L, et al. Juvenile and adult-onset acid maltase deficiency in France. Neurology. 2000;55(8):1122-1128.
27. Kostera-Pruszczyk, A, Opuchlik, A, Lugowska, A, Nadaj, A, Bojakowski, J, Tylki-Szymanska, A, et al. Juvenile onset acid maltase deficiency presenting as a rigid spine syndrome. Neuromuscul Disord. 2006;16(4):282-285.
28. Panosyan, FB, Fitzpatrick, MF, Bolton, CF. Late-onset Pompe disease mimicking rigid spine syndrome. Can J Neurol Sci. 2014;41(2):286-289.
29. Wens, SC, van Gelder, CM, Kruijshaar, ME, de Vries, JM, van der Beek, NA, Reuser, AJ, et al. Phenotypical variation within 22 families with Pompe disease. Orphanet J Rare Dis. 2013;8:182.
30. Alejaldre, A, Díaz-Manera, J, Ravaglia, S, Tibaldi, EC, D’Amore, F, Morís, G, et al. Trunk muscle involvement in late-onset Pompe disease: study of thirty patients. Neuromuscul Disord. 2012;22(Suppl 2):S148-S154.
31. Yanovitch, TL, Banugaria, SG, Proia, AD, Kishnani, PS. Clinical and histologic ocular findings in Pompe disease. J Pediatr Ophthalmol Strabismus. 2010;47(1):34-40.
32. Rosenow, EC 3rd, Engel, AG. Acid maltase deficiency in adults presenting as respiratory failure. Am J Med. 1978;64(3):485-491.
33. Sivak, ED, Salanga, VD, Wilbourn, AJ, Mitsumoto, H, Golish, J. Adult-onset acid maltase deficiency presenting as diaphragmatic paralysis. Ann Neurol. 1981;9(6):613-615.
34. Keunen, RW, Lambregts, PC, Op de Coul, AA, Joosten, EM. Respiratory failure as initial symptom of acid maltase deficiency. J Neurol Neurosurg Psychiatry. 1984;47(5):549-552.
35. Moufarrej, NA, Bertorini, TE. Respiratory insufficiency in adult-type acid maltase deficiency. South Med J. 1993;86(5):560-567.
36. Arad, M, Moskowitz, IP, Patel, VV, Ahmad, F, Perez-Atayde, AR, Sawyer, DB, et al. Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff–Parkinson–White syndrome in glycogen storage cardiomyopathy. Circulation. 2003;107(22):2850-2856.
37. Limongelli, G, Fratta, F. Cardiovascular involvement in Pompe disease. Acta Myol. 2011;30:202-203.
38. El-Gharbawy, AH, Bhat, G, Murillo, JE, Thurberg, BL, Kampmann, C, Mengel, KE, et al. Expanding the clinical spectrum of late-onset Pompe disease: dilated arteriopathy involving the thoracic aorta, a novel vascular phenotype uncovered. Mol Genet Metab. 2011;103(4):362-366.
39. Carpenter, S, Karpati, G. editors Pathology of Skeletal Muscle, 2nd ed. Oxford: Oxford University Press; 2001.
40. Dubowitz, V, Sewry, CA, Oldfors, A. Muscle Biopsy: A Practical Approach, 3rd ed. Amsterdam: Elsevier/Saunders; 2007.
41. Fernández, R, Fernández, JM, Cervera, C, Teijeira, S, Teijeiro, A, Domínguez, C, et al. Adult glycogenosis II with paracrystalline mitochondrial inclusions and Hirano bodies in skeletal muscle. Neuromuscul Disorders. 1999;9(3):136-143.
42. Sarnat, HB, Marin-Garcia, J. Pathology of mitochondrial encephalomyopathies. Can J Neurol Sci. 2005;32(2):152-166.
43. Schlenska, GK, Heene, R, Spalke, G, Seiler, D. The symptomatology, morphology and biochemistry of glycogenosis type II (Pompe) in the adult. J Neurol. 1976;212(3):237-252.
44. Werneck, LC, Lorenzoni, PJ, Kay, CS, Scola, RH. Muscle biopsy in Pompe disease. Arq Neuropsiquiatr. 2013;71(5):284-289.
45. Hobson-Webb, LD, Proia, AD, Thurberg, BL, Banugaria, S, Prater, SN, Kishnani, PS. Autopsy findings in late-onset Pompe disease: a case report and systematic review of the literature. Mol Genet Metab. 2012;106(4):462-469.
46. Martini, C, Ciana, G, Benettoni, A, Katouzian, F, Severini, GM, Bussani, R, et al. Intractable fever and cortical neuronal glycogen storage in glycogenosis type 2. Neurology. 2001;57(5):906-908.
47. Martin, JJ, de Barsy, T, van Hoof, F, Palladini, G. Pompe’s disease: an inborn lysosomal disorder with storage of glycogen. A study of brain and striated muscle. Acta Neuropathol. 1973;23(3):229-244.
48. Parise, G, Phillips, SM, Kaczor, JJ, Tarnopolsky, MA. Antioxidant enzyme activity is up-regulated after unilateral resistance exercise training in older adults. Free Radic Biol Med. 2005;39(2):289-295.
49. Vissing, J, Lukacs, Z, Straub, V. Diagnosis of Pompe disease: muscle biopsy vs. blood-based assays. JAMA Neurol. 2013;70(7):923-927.
50. Winkel, LP, Hagemans, ML, van Doorn, PA, Loonen, MC, Hop, WJ, Reuser, AJ, et al. The natural course of non-classic Pompe’s disease: a review of 225 published cases. J Neurol. 2005;252(8):875-884.
51. Mellies, U, Ragette, R, Schwake, C, Baethmann, M, Voit, T, Teschler, H. Sleep-disordered breathing and respiratory failure in acid maltase deficiency. Neurology. 2001;57(7):1290-1295.
52. Margolis, ML, Howlett, P, Goldberg, R, Eftychiadis, A, Levine, S. Obstructive sleep apnea syndrome in acid maltase deficiency. Chest. 1994;105(3):947-949.
53. American Association of Neuromuscular and Electrodiagnostic Medicine. Diagnostic criteria for late-onset (childhood and adult) Pompe disease. Muscle Nerve. 2009;40(1):149-160.
54. McCool, FD, Tzelepis, GE. Dysfunction of the diaphragm. New Engl J Med. 2012;366(10):932-942.
55. van der Beek, NA, van Capelle, CI, van der Velden-van Etten, KI, Etten, KI, Hop, WC, van den Berg, B, et al. Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease. Mol Genet Metab. 2011;104(1–2):129-136.
56. Pellegrini, N, Laforêt, P, Orlikowski, D, Pellegrini, M, Caillaud, C, Eymard, B, Raphael, JC, et al. Respiratory insufficiency and limb muscle weakness in adults with Pompe’s disease. Eur Respir J. 2005;26(6):1024-1031.
57. Roberts, M, Kishnani, PS, van der Ploeg, AT, Müller-Felber, W, Merlini, L, Prasad, S, et al. The prevalence and impact of scoliosis in Pompe disease: lessons learned from the Pompe Registry. Mol Genet Metab. 2011;104(4):574-582.
58. Cupler, EJ, Berger, KI, Leshner, RT, Wolfe, GI, Han, JJ, Barohn, RJ, et al. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve. 2012;45(3):319-333.
59. van den Berg, LE, Zandbergen, AA, van Capelle, CI, de Vries, JM, Hop, WC, van den Hout, JM, et al. Low bone mass in Pompe disease: muscular strength as a predictor of bone mineral density. Bone. 2010;47(3):643-649.
60. Ing, RJ, Cook, DR, Bengur, RA, Williams, EA, Eck, J, Dear Gde, L, et al. Anaesthetic management of infants with glycogen storage disease type II: a physiological approach. Paediatr Anaesth. 2004;14(6):514-519.
61. Wang, LY, Ross, AK, Li, JS, Dearmey, SM, Mackey, JF, Worden, M, et al. Cardiac arrhythmias following anesthesia induction in infantile-onset Pompe disease: a case series. Paediatr Anaesth. 2007;17(8):738-748.
62. Prater, SN, Banugaria, SG, Dearmey, SM, Botha, EG, Stege, EM, Case, LE, et al. The emerging phenotype of long-term survivors with infantile Pompe disease. Genet Med. 2012;14(9):800-810.
63. van der Ploeg, AT, Clemens, PR, Corzo, D, Escolar, DM, Florence, J, Groeneveld, GJ, Herson, S, et al. A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med. 2010;362(15):1396-1406.
64. Gungor, D, Kruijshaar, ME, Plug, I, D’Agostino, RB, Hagemans, ML, van Doorn, PA, et al. Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. Orphanet J Rare Dis. 2013;8:49.
65. Kansagra, S, Austin, S, DeArmey, S, Kishnani, PS, Kravitz, RM. Polysomnographic findings in infantile Pompe disease. Am J Med Genet A. 2013;161A(12):3196-3200.
66. van Gelder, CM, van Capelle, CI, Ebbink, BJ, Ebbink, BJ, Moor-van Nugteren, I, van den Hout, JM, et al. Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy. J Inherit Metab Dis. 2012;35(3):505-511.
67. Kishnani, PS, Corzo, D, Leslie, ND, Gruskin, D, van der Ploeg, A, Clancy, JP, et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res. 2009;66(3):329-335.
68. Chen, CA, Chien, YH, Hwu, WL, Lee, NC, Wang, JK, Chen, LR, et al. Left ventricular geometry, global function, and dyssynchrony in infants and children with Pompe cardiomyopathy undergoing enzyme replacement therapy. J Card Fail. 2011;17(11):930-936.
69. Bali, DS, Goldstein, JL, Banugaria, S, Dai, J, Mackey, J, Rehder, C, et al. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet C Semin Med Genet. 2012;160(1):40-49.
70. Banugaria, SG, Prater, SN, Ng, YK, Kobori, JA, Finkel, RS, Ladda, RL, et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med. 2011;13(8):729-736.
71. Kishnani, PS, Goldenberg, PC, DeArmey, SL, Heller, J, Benjamin, D, Young, S, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab. 2010;99(1):26-33.
72. Messinger, YH, Mendelsohn, NJ, Rhead, W, Dimmock, D, Hershkovitz, E, Champion, M, et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med. 2012;14(1):135-142.
73. Mendelsohn, NJ, Messinger, YH, Rosenberg, AS, Kishnani, PS. Elimination of antibodies to recombinant enzyme in Pompe’s disease. N Engl J Med. 2009;360(2):194-195.
74. Banugaria, SG, Prater, SN, Patel, TT, Dearmey, SM, Milleson, C, Sheets, KB, et al. Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile Pompe disease: a step towards improving the efficacy of ERT. PLoS One. 2013;8(6):e67052.
75. Moggio, M, Colombo, I, Peverelli, L, Villa, L, Xhani, R, Testolin, S, et al. Mitochondrial disease heterogeneity: a prognostic challenge. Acta Myol. 2014;33(2):86-93.
76. Regnery, C, Kornblum, C, Hanisch, F, Vielhaber, S, Strigl-Pill, N, Grunert, B, et al. 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy. J Inherit Metab Dis. 2012;35(5):837-845.
77. van der Ploeg, AT, Barohn, R, Carlson, L, Charrow, J, Clemens, PR, Hopkin, RJ, et al. Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. Mol Genet Metab. 2012;107(3):456-461.
78. de Vries, JM, van der Beek, NA, Hop, WC, Karstens, FP, Wokke, JH, de Visser, M, et al. Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J Rare Dis. 2012;7:73.
79. Toscano, A, Schoser, B. Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. J Neurol. 2013;260(4):951-959.
80. Anderson, LJ, Henley, W, Wyatt, KM, Nikolaou, V, Waldek, S, Hughes, DA, et al. Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS–LSD cohort study. J Inherit Metab Dis. 2014;37(6):945-952.
81. Angelini, C, Semplicini, C, Ravaglia, S, Bembi, B, Servidei, S, Pegoraro, E, et al. Observational clinical study in juvenile–adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol. 2012;259(5):952-958.
82. Strothotte, S, Strigl-Pill, N, Grunert, B, Kornblum, C, Eger, K, Wessig, C, et al. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol. 2010;257(1):91-97.
83. de Vries, JM, van der Beek, NA, Hop, WC, Karstens, FP, Wokke, JH, de Visser, M, et al. Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J Rare Dis. 2012;7(1):73.
84. Gungor, D, Schober, AK, Kruijshaar, ME, Plug, I, Karabul, N, Deschauer, M, et al. Pain in adult patients with Pompe disease: a cross-sectional survey. Mol Genet Metab. 2013;109(4):371-376.
85. Hagemans, ML, van Schie, SP, Janssens, AC, van Doorn, PA, Reuser, AJ, van der Ploeg, AT. Fatigue: an important feature of late-onset Pompe disease. J Neurol. 2007;254(7):941-945.
86. Gungor, D, de Vries, JM, Brusse, E, Kruijshaar, ME, Hop, WC, Murawska, M, et al. Enzyme replacement therapy and fatigue in adults with Pompe disease. Mol Genet Metab. 2013;109(2):174-178.
87. Case, LE, Bjartmar, C, Morgan, C, Casey, R, Charrow, J, Clancy, JP, et al. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease. Neuromuscul Disord. 2015;25(4):321-332.
88. Schoser, B, Laforêt, P, Kruijshaar, ME, Toscano, A, van Doorn, PA, van der Ploeg, AT, et al. 208th ENMC International Workshop: formation of a European network to develop a European data sharing model and treatment guidelines for Pompe disease. Naarden, The Netherlands, 26–28 September 2014. Neuromuscul Disord. 2015;25(8):674-678.
89. Hundsberger, T, Rohrbach, M, Kern, L, Rosler, KM. Swiss national guideline for reimbursement of enzyme replacement therapy in late-onset Pompe disease. J Neurol. 2013;260(9):2279-2285.
90. Patel, TT, Banugaria, SG, Case, LE, Wenninger, S, Schoser, B, Kishnani, PS. The impact of antibodies in late-onset Pompe disease: a case series and literature review. Mol Gen Metab. 2012;106(3):301-309.
91. de Vries, JM, van der Beek, NA, Kroos, MA, Ozkan, L, van Doorn, PA, Richards, SM, et al. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genet Metab. 2010;101(4):338-345.
92. Papadopoulos, C, Papadimas, GK, Spengos, K, Manta, P. Pretreatment antibodies against acid alpha-glycosidase in a patient with late-onset Pompe disease. Muscle Nerve. 2012;45(3):452.
93. El-Gharbawy, AH, Mackey, J, DeArmey, S, Westby, G, Grinnell, SG, Malovrh, P, et al. An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions. Mol Genet Metab. 2011;104(1–2):118-122.
94. Motlagh, B, MacDonald, JR, Tarnopolsky, MA. Nutritional inadequacy in adults with muscular dystrophy. Muscle Nerve. 2005;31(6):713-718.
95. Isaacs, H, Savage, N, Badenhorst, M, Whistler, T. Acid maltase deficiency: a case study and review of the pathophysiological changes and proposed therapeutic measures. J Neurol Neurosurg Psychiatry. 1986;49(9):1011-1018.
96. Umpleby, AM, Wiles, CM, Trend, PS, Chubb, D, Conaglen, JV, Williams, CD, et al. Protein turnover in acid maltase deficiency before and after treatment with a high protein diet. J Neurol Neurosurg Psychiatry. 1987;50(5):587-592.
97. Slonim, AE, Coleman, RA, McElligot, MA, Najjar, J, Hirschhorn, K, Labadie, GU, et al. Improvement of muscle function in acid maltase deficiency by high-protein therapy. Neurology. 1983;33(1):34-38.
98. Margolis, ML, Hill, AR. Acid maltase deficiency in an adult. Evidence for improvement in respiratory function with high-protein dietary therapy. Am Rev Respir Dis. 1986;134(2):328-331.
99. Demey, HE, van Meerbeeck, JP, Vandewoude, MF, Prové, AM, Martin, JJ, Bossaert, LL. Respiratory insufficiency in acid maltase deficiency: the effect of high-protein diet. J Parenter Enteral Nutr. 1989;13(3):321-323.
100. Umpleby, AM, Trend, PS, Chubb, D, Conaglen, JV, Williams, CD, Hesp, R, et al. The effect of a high-protein diet on leucine and alanine turnover in acid maltase deficiency. J Neurol Neurosurg Psychiatry. 1989;52(8):954-961.
101. Slonim, AE, Bulone, L, Goldberg, T, Minikes, J, Slonim, E, Galanko, J, et al. Modification of the natural history of adult-onset acid maltase deficiency by nutrition and exercise therapy. Muscle Nerve. 2007;35(1):70-77.
102. Ceglia, L. Vitamin D and skeletal muscle tissue and function. Mol Aspects Med. 2008;29(6):407-414.
103. Pascual, JM, Roe, CR. Systemic metabolic abnormalities in adult-onset acid maltase deficiency: beyond muscle glycogen accumulation. JAMA Neurol. 2013;70(6):756-763.
104. Khan, A, Weinstein, Z, Hanley, DA, Casey, R, McNeil, C, Ramage, B, et al. In vivo bone architecture in Pompe disease using high-resolution peripheral computed tomography. JIMD Rep. 2013;7:81-88.
105. Ross, AC, Manson, JE, Abrams, SA, Aloia, JF, Brannon, PM, Clinton, SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53-58.
106. Langlois, K, Greene-Finestone, L, Little, J, Hidiroglou, N, Whiting, S. Vitamin D status of Canadians as measured in the 2007 to 2009 Canadian Health Measures Survey. Health Rep. 2010;21(1):47-55.
107. Whiting, SJ, Langlois, KA, Vatanparast, H, Greene-Finestone, LS. The vitamin D status of Canadians relative to the 2011 Dietary Reference Intakes: an examination in children and adults with and without supplement use. Am J Clin Nutr. 2011;94(1):128-135.
108. Hanley, DA, Cranney, A, Jones, G, Whiting, SJ, Leslie, WD, Cole, DE, et al. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. CMAJ. 2010;182(12):E610-E618.
109. Holick, MF, Binkley, NC, Bischoff-Ferrari, HA, Gordon, CM, Hanley, DA, Heaney, RP, et al. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab. 2012;97(4):1153-1158.
110. Fromageot, C, Lofaso, F, Annane, D, Falaize, L, Lejaille, M, Clair, B, et al. Supine fall in lung volumes in the assessment of diaphragmatic weakness in neuromuscular disorders. Arch Phys Med Rehabil. 2001;82(1):123-128.
111. Mier-Jedrzejowicz, A, Brophy, C, Moxham, J, Green, M. Assessment of diaphragm weakness. Am Rev Respir Dis. 1988;137(4):877-883.
112. Prigent, H, Orlikowski, D, Laforêt, P, Letilly, N, Falaize, L, Pellegrini, N, et al. Supine volume drop and diaphragmatic function in adults with Pompe disease. Eur Respir J. 2012;39(6):1545-1546.
113. Ragette, R, Mellies, U, Schwake, C, Voit, T, Teschler, H. Patterns and predictors of sleep-disordered breathing in primary myopathies. Thorax. 2002;57(8):724-728.
114. Heritier, F, Rahm, F, Pasche, P, Fitting, JW. Sniff nasal inspiratory pressure: a noninvasive assessment of inspiratory muscle strength. Am J Respir Crit Care Med. 1994;150(6 Pt 1):1678-1683.
115. Stefanutti, D, Benoist, MR, Scheinmann, P, Chaussain, M, Fitting, JW. Usefulness of sniff nasal pressure in patients with neuromuscular or skeletal disorders. Am J Respir Crit Care Med. 2000;162(4 Pt 1):1507-1511.
116. Szeinberg, A, Tabachnik, E, Rashed, N, McLaughlin, FJ, England, S, Bryan, CA, et al. Cough capacity in patients with muscular dystrophy. Chest. 1988;94(6):1232-1235.
117. Bach, JR, Ishikawa, Y, Kim, H. Prevention of pulmonary morbidity for patients with Duchenne muscular dystrophy. Chest. 1997;112(4):1024-1028.
118. Sancho, J, Servera, E, Díaz, J, Marin, J. Predictors of ineffective cough during a chest infection in patients with stable amyotrophic lateral sclerosis. Am J Respir Crit Care Med. 2007;175(12):1266-1271.
119. Miller, MR, Hankinson, J, Brusasco, V, Burgos, F, Casaburi, R, Coates, A, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319-338.
120. McKim, DA, Road, J, Avendano, M, Abdool, S, Cote, F, Duguid, N, et al. Home mechanical ventilation: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2011;18(4):197-215.
121. Simonds, AK, Muntoni, F, Heather, S, Fielding, S. Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy. Thorax. 1998;53(11):949-952.
122. Mellies, U, Stehling, F, Dohna-Schwake, C, Ragette, R, Teschler, H, Voit, T. Respiratory failure in Pompe disease: treatment with noninvasive ventilation. Neurology. 2005;64(8):1465-1467.
123. Annane, D, Quera-Salva, MA, Lofaso, F, Vercken, JB, Lesieur, O, Fromageot, C, et al. Mechanisms underlying effects of nocturnal ventilation on daytime blood gases in neuromuscular diseases. Eur Respir J. 1999;13(1):157-162.
124. Ward, S, Chatwin, M, Heather, S, Simonds, AK. Randomised controlled trial of non-invasive ventilation (NIV) for nocturnal hypoventilation in neuromuscular and chest wall disease patients with daytime normocapnia. Thorax. 2005;60(12):1019-1024.
125. Chadda, K, Clair, B, Orlikowski, D, Macadoux, G, Raphael, JC, Lofaso, F. Pressure support versus assisted controlled noninvasive ventilation in neuromuscular disease. Neurocrit Care. 2004;1(4):429-434.
126. Toussaint, M, Steens, M, Wasteels, G, Soudon, P. Diurnal ventilation via mouthpiece: survival in end-stage Duchenne patients. Eur Respir J. 2006;28(3):549-555.
127. Nilsson, MI, Samjoo, IA, Hettinga, BP, Koeberl, DD, Zhang, H, Hawke, TJ, et al. Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease. Mol Genet Metab. 2012;107(3):469-479.
128. Terzis, G, Dimopoulos, F, Papadimas, GK, Papadopoulos, C, Spengos, K, Fatouros, I, et al. Effect of aerobic and resistance exercise training on late-onset Pompe disease patients receiving enzyme replacement therapy. Mol Genet Metab. 2011;104(3):279-283.
129. Terzis, G, Krase, A, Papadimas, G, Papadopoulos, C, Kavouras, SA, Manta, P. Effects of exercise training during infusion on late-onset Pompe disease patients receiving enzyme replacement therapy. Mol Genet Metab. 2012;107(4):669-673.
130. Burns, PB, Rohrich, RJ, Chung, KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstructr Surg. 2011;128(1):305-310.
131. Tarnopolsky, M, Zimmer, A, Paikin, J, Safdar, A, Aboud, A, Pearce, E, et al. Creatine monohydrate and conjugated linoleic acid improve strength and body composition following resistance exercise in older adults. PloS One. 2007;2(10):e991.
132. Jones, HN, Moss, T, Edwards, L, Kishnani, PS. Increased inspiratory and expiratory muscle strength following respiratory muscle strength training (RMST) in two patients with late-onset Pompe disease. Mol Genet Metab. 2011;104(3):417-420.
133. Anziska, Y, Sternberg, A. Exercise in neuromuscular disease. Muscle Nerve. 2013;48(1):3-20.
134. Hagemans, ML, Janssens, AC, Winkel, LP, Sieradzan, KA, Reuser, AJ, van Doorn, PA, et al. Late-onset Pompe disease primarily affects quality of life in physical health domains. Neurology. 2004;63(9):1688-1692.
135. Hagemans, ML, Laforêt, P, Hop, WJ, Merkies, IS, van Doorn, PA, Reuser, AJ, et al. Impact of late-onset Pompe disease on participation in daily life activities: evaluation of the Rotterdam Handicap Scale. Neuromuscul Disord. 2007;17(7):537-543.
136. Haley, SM, Fragala, MA, Skrinar, AM. Pompe disease and physical disability. Dev Med Child Neurol. 2003;45(9):618-623.
137. Laberge, L, Mathieu, J, Auclair, J, Gagnon, E, Noreau, L, Gagnon, C. Clinical, psychosocial, and central correlates of quality of life in myotonic dystrophy type 1 patients. Eur Neurol. 2013;70(5–6):308-315.
138. Tieleman, AA, Jenks, KM, Kalkman, JS, Borm, G, van Engelen, BG. High disease impact of myotonic dystrophy type 2 on physical and mental functioning. J Neurol. 2011;258(10):1820-1826.
139. van der Beek, NA, Hagemans, ML, van der Ploeg, AT, van Doorn, PA, Merkies, IS. The Rasch-built Pompe-specific activity (R–PAct) scale. Neuromuscul Disord. 2013;23(3):256-264.
140. Manwaring, V, Prunty, H, Bainbridge, K, Burke, D, Finnegan, N, Franses, R, et al. Urine analysis of glucose tetrasaccharide by HPLC; a useful marker for the investigation of patients with Pompe and other glycogen storage diseases. J Inherit Metab Dis. 2012;35(2):311-316; Erratum in J Inherit Metab Dis. 2012;35(2):369.
141. Young, SP, Zhang, H, Corzo, D, Thurberg, BL, Bali, D, Kishnani, PS, et al. Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker. Genet Med. 2009;11(7):536-541.
142. Young, SP, Stevens, RD, An, Y, Chen, YT, Millington, DS. Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilution-electrospray ionization tandem mass spectrometry. Anal Biochem. 2003;316(2):175-180.
143. Young, SP, Piraud, M, Goldstein, JL, Zhang, H, Rehder, C, Laforêt, P, et al. Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques. Am J Med Genet C Semin Med Genet. 2012;160C(1):50-58.
144. Chien, YH, Goldstein, JL, Hwu, WL, Smith, PB, Lee, NC, Chiang, SC, et al. Baseline urinary glucose tetrasaccharide concentrations in patients with infantile- and late-onset Pompe disease identified by newborn screening. JIMD Rep. 2015;19:67-73.
145. Bushby, K, Finkel, R, Birnkrant, DJ, Case, LE, Clemens, PR, Cripe, L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9(1):77-93.
146. Maga, JA, Zhou, J, Kambampati, R, Peng, S, Wang, X, Bohnsack, RN, et al. Glycosylation-independent lysosomal targeting of acid alpha-glucosidase enhances muscle glycogen clearance in Pompe mice. J Biol Chem. 2013;288(3):1428-1438.
147. Zhu, Y, Li, X, Kyazike, J, Zhou, Q, Thurberg, BL, Raben, N, et al. Conjugation of mannose 6-phosphate-containing oligosaccharides to acid alpha-glucosidase improves the clearance of glycogen in Pompe mice. J Biol Chem. 2004;279(48):50336-50341.
148. Koeberl, DD, Luo, X, Sun, B, McVie-Wylie, A, Dai, J, Li, S, et al. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle. Mol Genet Metab. 2011;103(2):107-112.
149. Khanna, R, Flanagan, JJ, Feng, J, Soska, R, Frascella, M, Pellegrino, LJ, et al. The pharmacological chaperone AT2220 increases recombinant human acid alpha-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease. PLoS One. 2012;7(7):e40776.



Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed